Correspondence 0001104659-23-036084 from GridAI Technologies Corp. (GRDX)
GridAI Technologies Corp.
Date: March 23, 2023 · CIK: 0001604191 · Accession: 0001104659-23-036084
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270723
Letter
Re:
March 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
First Wave BioPharma, Inc. (the “Company”)
Registration Statement on Form S-3 (File No. 333-270723)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on March 27, 2023, or as soon as practicable thereafter.
Please call Jack Hogoboom of Lowenstein Sandler LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
FIRST WAVE BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
March 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
First Wave BioPharma, Inc. (the “Company”)
Registration Statement on Form S-3 (File No.
333-270723)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on March 27, 2023, or as
soon as practicable thereafter.
Please call Jack Hogoboom
of Lowenstein Sandler LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
FIRST WAVE BIOPHARMA, INC.
By:
/s/ James Sapirstein
Name:
James Sapirstein
Title:
President, Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)